Clemastin
Chronic Progressive Multiple Sclerosis
Explore 12 assets in Chronic Progressive Multiple Sclerosis →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
University of California, San Francisco
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05359653CT.gov Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Progressive Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clemastin (this asset) | University of California, San Francisco | P1/2 | CCC · 48 |
| D-Thioctic Acid | Rebecca Spain | P2/3 | BB |
| Cyclophosphamide | Bruce Cree | P3 | BB |
| Rituximab | Centre Hospitalier de PAU | P2 | B |
| Masitinib | AB Science | P3 | B |
| Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors | Brainstorm-Cell Therapeutics | P2 | B |
| Cladribine | Queen Mary University of London | P2/3 | B |
| Acetylcysteine | University of California, San Francisco | P2 | B |
| Gerpevir | Sanofi | P1 | CCC |
+21 more in the Chronic Progressive Multiple Sclerosis cohort
Other indications for Clemastin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P2 | B · 61 |
| Multiple Sclerosis | — | P3 | B · 60 |
| Internuclear Ophthalmoplegia | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clemastin in Chronic Progressive Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clemastin-chronic-progressive-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →